Literature DB >> 31543154

Complement inhibitors are not useful in secondary hemolytic uremic syndromes.

Caroline Duineveld1, Jack F M Wetzels2.   

Abstract

Entities:  

Year:  2019        PMID： 31543154     DOI： 10.1016/j.kint.2019.08.001

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  5 in total

1.  The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.

Authors:  Magnus Holter Bjørkto; Andreas Barratt-Due; Ingvild Nordøy; Christina Dörje; Eivind Galteland; Andreas Lind; Abdulkarim Hilli; Pål Aukrust; Geir Mjøen
Journal:  BMC Infect Dis       Date:  2021-02-01       Impact factor: 3.090

2.  C5 Inhibition in Secondary Thrombotic Microangiopathies: A Yet Unresolved Question.

Authors:  Alexis Werion; Eric Rondeau
Journal:  Kidney Int Rep       Date:  2021-02-22

3.  Application of C5 inhibitors in glomerular diseases in 2021.

Authors:  Alexis Werion; Eric Rondeau
Journal:  Kidney Res Clin Pract       Date:  2022-03-15

4.  Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.

Authors:  Mi Jung Kim; Haekyung Lee; Yon Hee Kim; So Young Jin; Hee-Jin Kim; Doyeun Oh; Jin Seok Jeon
Journal:  BMC Nephrol       Date:  2021-03-10       Impact factor: 2.388

5.  Haemolytic uraemic syndrome associated with pancreatitis: report of four cases and review of the literature.

Authors:  Justo Sandino-Pérez; Eduardo Gutiérrez; Fernando Caravaca-Fontán; Enrique Morales; Lucia Aubert-Girbal; Ramón Delgado-Lillo; Manuel Praga
Journal:  Clin Kidney J       Date:  2021-01-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.